COMPLETED

An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423

NCT01316679•Vanderbilt University Medical Center

Summary

Specific urine proteases or groups of these enzymes can be reliable biomarkers and an effective gauge of response to therapy in patients with hepatocellular carcinoma.

Eligibility

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Ability and willingness to provide written informed consent
•Must be between 18-90 years of age at the time of consent
•Ability to provide urine specimen at protocol-defined timepoints
•Must have treatment interventions planned that are directly related to liver disease (excluding those assigned to group 3-Controls)

Exclusion Criteria

•Suspected inability, e.g. unwillingness to comply with study procedures or unwillingness to provide written consent

Key Dates

Start Date

March 1, 2011

Primary Completion Date

January 1, 2013

Completion Date

January 1, 2013

Last Updated

April 12, 2017

Enrollment

87

ACTUAL participants

Conditions

Hepatocellular CarcinomaLiver Disease

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

RECRUITING

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 12, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITINGPHASE1/PHASE2